Operator: Good day and thank you for standing by. Welcome to the Quanterix Corporation Q3 2023 Earnings Call. At this time, all participants are in a listen-only mode.
In this interview, Remo Panaccione, MD, discusses results from the long-term extension of the GALAXI phase 2 study for guselkumab in Crohn disease and their implications in clinical practice.
During the long-term extension of the GALAXI trial, 54.1% of participants treated with guselkumab achieved clinical remission and 34.7% achieved endoscopic response.